Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MKC-442 (Emivirine) with d4T, ddI, and Hydroxyurea in HIV
NCT00002412Phase 2Completed
- Sponsor
- Triangle Pharmaceuticals, Inc.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing MKC-442 Arm with Placebo Arm (2 arms). Primary endpoints: Safety and Tolerability at 48 weeks and Antiviral Efficacy at 48 weeks. Status: completed.
02
Drugs
Emivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002412.